Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes
Condition(s):Tau Distributions in Patients With Tauopathy Using APN-1607 PET ScanLast Updated:November 28, 2022Unknown status
Hide Studies Not Open or Pending
Condition(s):Tau Distributions in Patients With Tauopathy Using APN-1607 PET ScanLast Updated:November 28, 2022Unknown status
Condition(s):TauopathiesLast Updated:March 12, 2024Recruiting
Condition(s):TauopathiesLast Updated:October 17, 2023Recruiting
Condition(s):TauopathiesLast Updated:March 5, 2024Recruiting
Condition(s):TauopathiesLast Updated:November 6, 2017Completed
Condition(s):ParkinsonismLast Updated:January 27, 2021Completed
Condition(s):Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)Last Updated:August 20, 2019No longer available
Condition(s):Progressive Supranuclear Palsy (PSP); Corticobasal Degeneration (CBD); Frontotemporal Dementia (FTD MAPT Mutation)Last Updated:April 13, 2022Completed
Condition(s):Predicted Tauopathies, Including; Progressive Supranuclear Palsy; Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17; Corticobasal Degeneration Syndrome; Progressive Nonfluent AphasiaLast Updated:April 5, 2019Completed
Condition(s):Progressive Supranuclear Palsy; Multi-System Atrophy; ParkinsonismLast Updated:February 4, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.